Creative Bio-Peptides, Inc., an emerging drug development company focused on the development of leading-edge multi-chemokine antagonist therapeutic peptides for neuroinflammatory/neurodegenerative conditions, has been awarded $5.8M in non-dilutive funding from three NIH agencies.
BioHealth Capital Region Spotlight: Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications
